Clinical Trial Search

Primary: Baseline-adjusted Cmax of PTH(1-84) — 295.662; 330.820; 175.468; 99.708 Picogram per milliliter (pg/mL)

Primary: Maximum Observed Concentration (Cmax) of UPB-101 — 11.6; 24.4; 35.1; 34.9 ug/mL

Primary: Maximum Rates of Extensor Digitorum Brevis (EDB) Muscle M-Wave Amplitude Reduction From Baseline — 9.02; 48.53; 70.95; 81.62 Percentage of Reduction

Primary: Cmax of BIA 9-1067 - Maximum Observed Plasma Concentration of BIA 9-1067 (Day 1) — 182; 794; 1540; 176 ng/mL

Primary: SRD Part - Number of Subjects With Drug-related Adverse Events — 0; 0; 0; 0 Participants

Primary: Percentage of Subjects With Drug-related Adverse Events — 22.2; 33.3; 0.0; 0.0 Percentage of subjects

Primary: Number of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE) — 1; 0; 2; 1 Participants

Primary: Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve (AUC) of LY2484595 — 12200; 17800; 17800 hours times nanograms per milliliter

Primary: Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious AEs During the Single-Dose (SD) Period — 0; 0; 0; 0 participants

Primary: Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] of Crizotinib — 1423; 3806; 6569 ng*hr/mL

Primary: Percentage (%) of Subjects With Drug-related Adverse Events (AEs) — 13.3; 9.1; 36.4; 57.9 Percentage of Participants

Primary: Geometric Mean Fold Rise (GMFR) From Baseline in Antibody Level — 4.4; 0.9 Ratio

Primary: Number of Participants With Solicited Injection Site and Systemic Adverse Events — 1; 2; 1; 3 participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs , and TEAEs Leading to Participant Discontinuation From Study — 0; 3; 0; 0…

Primary: Maximum Observed Plasma Concentration (Cmax) — 456; 483 nanogram per millileter (ng/mL)

Primary: Rate of Iron Excretion. — 1.07; 1.69; 1.08 milligrams per day — p=< 0.05

Primary: Total Body Water — 1.85 liter

Primary: The Ratio of D4-hydroxy Acid to D4- NNAL (an Estimate if NNK Alpha Hydroxylation) — 0.133; 0.175 Ratio

Primary: Percentage of Participants Receiving Subcutaneous Vaccination Who Achieved Seroprotection — 90.1; 82.5 Percentage of participants

Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 0.0; 0.0; 0.0; 5.6 Percentage of participants

Primary: Number of Participants With Investigator Defined Drug-related Adverse Events — 2; 1; 4; 2 Participants

Primary: Number of Subjects With Drug-Related Adverse Events (AEs) — 1; 0; 0; 0 Participants

Primary: Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) — 0; 1; 0; 0 Participants

Primary: Exponential Rate of Change in Serum Potassium (S-K) Values During the Initial 48 Hours of Study Drug Treatment — -0.00273; -0.00508; -0.00012 log (mmol/L) / hour…

Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 25; 0; 16.7; 0 Percentage of participants

Primary: Plasma 25-hydroxy Vitamin D (25(OH)D) Level (Nmol/L) — 116.7; 181.3; 46.1; 52.8 nmol/L

Primary: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) — 2070; 3740 hours*nanomoles/Liter…

Primary: Measure the Maximum (Peak) Plasma Concentration of the Drug (Cmax) — 8.88 ng/mL

Primary: Safety (Physical Examination, Vital Signs, ECG, Haematology, Biochemistry, Urinalysis, Coagulation Factors, Coagulation-related Parameters, Injection Site Tolerability…

Primary: Number (%) of Subjects With Drug-related Adverse Events — 28.0; 51.9; 33.3; 92.6 Percentage of participants